Trials / Recruiting
RecruitingNCT06517199
Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- Sponsor
- Mahidol University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine 2.5 MG | olanzapine 2.5 mg/day for 28 days |
| DRUG | Olanzapine 5 MG | olanzapine 5 mg/day for 28 days |
| DRUG | Placebo | placebo 1 tab/day for 28 days |
Timeline
- Start date
- 2024-01-22
- Primary completion
- 2026-01-21
- Completion
- 2026-01-21
- First posted
- 2024-07-24
- Last updated
- 2024-07-24
Locations
2 sites across 1 country: Thailand
Source: ClinicalTrials.gov record NCT06517199. Inclusion in this directory is not an endorsement.